This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
ARV-771
Catalog No. T5435 CAS
1949837-12-0
ARV-771 is a potent BET degrader based on PROTAC technology with Kds of 34, 4.7, 8.3, 7.6, 9.6, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively[1].
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
ARV-771 is a potent BET degrader based on PROTAC technology with Kds of 34, 4.7, 8.3, 7.6, 9.6, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively[1].
ARV-771, utilizing proteolysis-targeting chimera (PROTAC) technology, outperforms BET inhibitors in CRPC cellular models by effectively degrading BRD2/3/4 in 22Rv1 cells with a DC50 of less than 5 nM. This compound also significantly reduces c-MYC protein levels, a key BET protein effector, achieving an IC50 under 1 nM. Demonstrating potent anti-proliferative abilities, ARV-771 impacts 22Rv1, VCaP, and LnCaP95 cell lines, inducing apoptosis and altering cell morphology. Furthermore, treatment with 10 nM of ARV-771 notably suppresses FL-AR and AR-V7 mRNA in VCaP cells and exerts an antiandrogenic influence on several AR-regulated genes within these cells[1].
In vivo
Administering daily subcutaneous injections of ARV-771 at a dosage of 10 mg/kg for three days to non-castrated male Nu/Nu mice with AR-V7+ 22Rv1 tumor xenografts resulted in a significant reduction of BRD4 and c-MYC levels in the tumor tissue by 37% and 76%, respectively. Additionally, a notable decrease in AR-V7 levels was observed in the 22Rv1 tumors following the treatment with ARV-771[1].
Molecular Weight
986.64
Formula
C49H60ClN9O7S2
CAS No.
1949837-12-0
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.